文章核心观点 公司首席执行官Robert Hayes致信股东，请求投票批准三项对公司持续增长至关重要的提案，通过提案对执行增长战略和为股东创造价值极为重要 [1] 提案内容 - 增加普通股授权股数，用于未来股权交易 [5] - 酌情进行最高1比8的反向股票分割，以维持纳斯达克上市资格 [5] - 进行非公开发行证券，最大折扣不超过公司普通股市场价格的20% [5] 投票方式 - 可通过互联网在www.proxyvote.com投票，需持有16位股东控制号 [2] - 可通过免费电话1 - 800 - 690 - 6903投票，需持有16位股东控制号 [2] - 股份由经纪商或银行持有，需直接联系获取16位股东控制号 [2] - 投票问题和咨询可联系经纪商，持有注册股份可发邮件至info@sharpstechnology.com或致电(631) 574 - 4436 [2] 投票时间 - 截至2024年7月12日美国东部时间晚上11:59，5月17日登记在册的股东可随时投票或更改投票 [6] - 7月15日特别会议期间可通过www.virtualshareholdermeeting.com/STSS2024SM进行迟到投票或更改投票，需16位股东控制号 [7] 公司现状与前景 - 注射器市场发展使公司创新产品受关注，公司正积极把握医疗市场机会 [8] - 公司有能力为美国和全球医疗客户提供创新产品，南卡罗来纳州的制造扩张预计12个月内可向市场供应预填充注射器 [8]

文章核心观点 - 夏普斯科技公司向拉丁美洲医疗市场首次发运Securegard智能安全注射器，有望促进该地区安全医疗实践，提升医疗质量 [2][1][3] 公司动态 - 夏普斯科技公司是创新医疗设备和药品包装公司，拥有专利注射器产品，已向拉丁美洲医疗市场首次发运1mL和3mL的Securegard智能安全注射器 [2] - 初始产品订单是夏普斯与哥伦比亚的拉丁美洲分销合作伙伴共同努力达成，合作将使Securegard注射器系列面向医院、药房和直接销售点，让医疗网络能利用该技术并体验其实际效益 [6] 产品优势 - Securegard注射器为临床医生提供超低浪费药物输送技术，具备主动安全功能和世卫组织认可的防复用措施，可保护一线医护人员免受针刺伤害、公众免受针头复用危险，还能使患者获得更多药物治疗 [3] - Securegard注射器将安全和防复用功能融入设计，为医疗市场、机构和供应商提供有前景的药物输送解决方案，超低浪费技术能确保为有需求的人提供最大剂量的所需药物疗法 [9] 公司展望 - 公司认为此次发货是在拉丁美洲分销网络建立战略伙伴关系的重要一步，相信医护人员使用Securegard注射器后会长期订购，带来长期采购订单和交付 [1] - 该技术引入拉丁美洲可提升当地医疗整体质量水平，为其他地区采用可持续和安全医疗实践树立积极榜样 [3][9]

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-inclass syringe products, has made the first shipment of its 1mL and 3mL Securegard smart safety syringe line to the Latin American healthcare market. The initial product orders were placed through a collaborative effort between Sharps and a Latin American distribution partner based in Colombia and represent a significant ...

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-inclass syringe products, is pleased to invite investors to a webinar on June 18, 2024, at 4:15 p.m. ET. Additionally, a five-year, $200 million sales agreement with Nephron will see Sharps' next-generation copolymer prefillable syringes manufactured at the South Carolina plant and 10mL SoloGard polypropylene syringes fro ...

Current Asset Purchase Agreement closing timeline is on track for expected prefillable syringe product shipments to begin by Q2 of 2025. Braden Miller, Sharps Director of Product Development, commented, "Sharps has developed an exciting alternative to glass syringes through the use of molded inert polymers, offering a high-quality solution compared to traditional glass syringe systems." Sharps prefillable polymer syringes have many of the same characteristics as traditional glass designs to support long ter ...

Signed PO secures first 12 months of syringe product orders against Sharps and Nephron's five-year, $200 million Syringe Sales Agreement. Braden Miller, Sharps Director of Product Development, commented, "Sharps has developed an exciting alternative to glass syringes through the use of molded inert polymers, offering a high-quality solution compared to traditional glass syringe systems." Sharps prefillable polymer syringes have many of the same characteristics as traditional glass designs to support long te ...

InjectEZ acquisition establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. has progressed with the payment of $1 million into third-party escrow account. Closing on the Asset Purchase and the Syringe Sales Agreement, for product orders totaling over $200 million for the first five years of operation, is expected within the next 60 days. Based on the most likely timeframe, product shipments from the SC facility are planned to begin by Q2 of 2025. NEW YORK, June 05, 2024 (GLOBE NE ...

Sharps CEO issues letter to shareholders with details about the InjectEZ acquisition, establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. Signed Syringe Sales Agreement will secure product orders totaling over $200 million for the first five years of operation. Sharps is negotiating additional pharma-segment purchase commitments for orders over the next three years, with shipments expected to begin by Q2 of 2025. Demand for Sharps products is increasing due to recent FDA warni ...

Sharps will strengthen its manufacturing capacity with a $35 million acquisition of assets, establishing the Company's position in the specialized copolymer prefillable syringe (PFS) system industry in the U.S. Through the syringe Sales Agreement and the closing of the APA, Sharps will secure product orders totaling over $200 million for the first five years of operation Sharps is negotiating additional pharma-segment PFS purchase commitments for orders over the next 3 years, with shipments expected to begi ...

Sharps will strengthen its manufacturing capacity with a $35 million acquisition of assets, establishing the Company's position in the specialized copolymer prefillable syringe (PFS) system industry in the U.S. Through the syringe Sales Agreement and the closing of the APA, Sharps will secure product orders totaling over $200 million for the first five years of operation Sharps is negotiating additional pharma-segment PFS purchase commitments for orders over the next 3 years, with shipments expected to begi ...